Ten patients with progressive, symptomatic interstitial lung disease of unknown aetiology who were treated with cyclosporin A were reviewed. Five had clinical and histopathological features of cryptogenic fibrosing alveolitis and five a progressive restrictive lung disease characterised by interstitial infiltration with lymphocytes and minimal fibrosis, which could not be classified precisely.
progressive restrictive lung disease characterised by interstitial infiltration with lymphocytes and minimal fibrosis, which could not be classified precisely. Three patients with lymphocytic infiltration showed a response to initial treatment with cyclosporin A alone at high dosage, but toxicity precluded further treatment. All 10 patients then received low doses of cyclosporin A and prednisone. Three of the patients with cryptogenic fibrosing alveolitis and all five patients with lymphocytic infiltration responded with a reduction in dyspnoea or an increase in vital capacity, or both; cyclosporin A appeared to be effective, or at least to have a corticosteroid potentiating effect. A high incidence of side effects occurred, though these Subsequently all 10 patients were treated with a combination of cyclosporin A 7 mg/kg/ day and prednisone 20 mg/day. These doses were maintained for eight to 10 weeks and then reduced slowly over the following two months to a minimum maintenance dose of 3 mg/kg/day for cyclosporin A and 10 mg/day for prednisone. Combined treatment lasted six to 47 (median 22) months.
Patients were examined clinically at monthly intervals, to determine side effects of cyclosporin A. Serum urea, creatinine, and electrolyte concentrations were determined and a full blood count and liver function tests performed at every visit. Lung function measurements were repeated at monthly intervals and chest radiographs obtained after the first three months and subsequently at six monthly intervals. Vital capacity and forced expiratory volume in one second (FEV,) were corrected to BTPS and expressed as a percentage of the predicted value for sex, age, and height. Blood concentrations of cyclosporin A were determined at each visit to check compliance with treatment.
EVALUATION OF RESPONSE
The response to cyclosporin A treatment was assessed on the basis of symptomatic and physiological criteria. Symptomatic dyspnoea was graded according to the New York Heart Association's criteria.'7 A change of one full grade of dyspnoea constituted a symptomatic response. A 10% change in forced vital capacity (FVC) constituted physiological improvement or deterioration.2 A therapeutic response was defined as a change in dyspnoea or FVC or both at three or six months that persisted for at least three more months. A one grade increase in dyspnoea or a 10% decrease in FVC maintained for two consecutive months constituted a relapse. (table 2) . Five showed an improvement in both measures and three in one measure. One patient showed a deterioration in both measurements, and one was regarded as stable.
Ofthe five patients with classical cryptogenic fibrosing alveolitis, three (Nos 1, 2, and 3) responded, but only one (No 3) showed an improvement in both symptoms and lung function. All five patients with a cellular histological appearance and minimal fibrosis responded to the combination of cyclosporin A and prednisone, four showing an improvement in both measurements. Permanent remission was not achieved after treatment for 24-36 months and relapse after cessation of the combined treatment suggests that indefinite treatment may be indicated. In one patient with a pronounced honeycombing pattern on the chest radiograph combined treatment may have caused sufficient immunosuppression to allow infection to occur. Toxic effects of cyclosporin A on the kidney can be reversed by reducing the dose, but hypertension in our patients required long term treatment. We do not believe that these complications in some patients preclude the use of low dose cyclosporin A and prednisone, given the side effects of other immunosuppressant combinations.
The combination of low doses of cyclosporin A and prednisone was effective in some patients with cryptogenic fibrosing alveolitis and in patients with lymphocytic interstitial lung disease with minimal fibrosis; but the limitations of a non-randomised study and small numbers of patients must be taken into account when these results are assessed. More information is required to assess the benefits of combined treatment for an extended period. lung disease of unknown aetiology. 
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